SovaSage Releases AI-Powered Tool for CPAP Patient Management
A new machine learning-driven feature analyzes therapy variables to help identify patients who may need additional clinical assessment.
A new machine learning-driven feature analyzes therapy variables to help identify patients who may need additional clinical assessment.
Nexalin Technology has secured a US patent for its Deep Intracranial Frequency Stimulation (DIFS) platform, protecting its noninvasive, in-home treatment method for insomnia, anxiety, and depression through 2042. The patent reinforces the company’s strategy to expand physician-supervised, drug-free neurostimulation care via its virtual clinic model.
Research presented at ATS 2026 reveals that positional therapy conditions patients to avoid back-sleeping, maintaining obstructive sleep apnea control for up to a year after device withdrawal.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.